Today BICO, the leading bio convergence company, announced it will, based on Nasdaq’s annual review of the market capitalization segments, be moved from the Mid Cap to the Large Cap segment on January 3, 2022.

“This move to Nasdaq Stockholm’s large cap segment is a testament BICO’s strong growth and momentum in the last year,” says Erik Gatenholm, CEO and co-founder of BICO. “We are continuing to develop our bio convergence offering enabling our customers to achieve Health 4.0. and create the future of health.”

The move comes just five years after the company was first listed on the Nasdaq First North exchange at a valuation of just above MSEK 150. In the previous year, BICO saw strong momentum both in acquired and organic growth including adding 9 leading life science organizations to its group. The group also added more than 600 employees across the parent and group companies and saw more than 69 percent organic growth from Q1-Q3, 2021.

For further information, please contact:

BICO Press office US 
Riley Munks, PR Manager: +1 (650) 863-6699
Alyssa D’Orazio, PR Manager: +1 (617) 634-9601

Email: press@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on December 20, 2021, at 09:05 (CET).

About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. 

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. 

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com